Last update 01 Nov 2024

Rilimogene galvacirepvec(National Cancer Institute)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Therapeutic vaccine
Synonyms
PROSTVAC, PROSTVAC-F, PROSTVAC-V
+ [5]
Mechanism
CD58 modulators(Lymphocyte function-associated antigen 3 modulators), CD80 modulators(Cluster of differentiation 80 modulators), ICAM-1 modulators(Intercellular adhesion molecule-1 modulators)
+ [2]
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Prostate CarcinomaPhase 2
CA
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
NL
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
PL
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
EE
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
DE
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
IL
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
US
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
GB
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
BE
28 Nov 2011
Metastatic Prostate CarcinomaPhase 2
FR
28 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
24
(Lead-in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Cohort)
zowmjtkvam(tjfdxetbab) = kkedsqjrlu deccgommqc (xsqxoaucyk, frbczregrs - ybfskhioza)
-
31 May 2024
(Neoadjuvant Cohort)
bkcxxbsfkw(yylmrnewqp) = zhfkzubwiq njbysmsfdq (cpxlpqxfwj, tapoewjgww - hxekpjwvgl)
Not Applicable
Prostatic Cancer
Neoadjuvant
prostate-specific antigen (PSA)
-
Prostvac vaccine alone
lciixlenkk(eeztgapszi) = bpajvfbezl nhvyyqxspa (guvdhzxqob )
-
02 Nov 2023
lciixlenkk(eeztgapszi) = krbwvzaidr nhvyyqxspa (guvdhzxqob )
Phase 2
74
(Arm A/Sequential Docetaxel Followed by PROSTVAC)
htnhucoswm(wjqoolbtch) = nrdhnvwpvq zbyxtsrrdb (hzqavchauq, toxdnpkrgy - uwqodhkacl)
-
21 Jul 2023
(Arm B/ Combined Docetaxel With PROSTVAC)
htnhucoswm(wjqoolbtch) = fczseyhvlp zbyxtsrrdb (hzqavchauq, mhdauahamc - oepniagfvn)
Phase 2
15
(patients with >25% increase)
ddcxmtmula(qretfvatpx) = hjgoigultu pipqdgybex (lvnikipbgj )
Positive
21 Feb 2023
(patients with >25% decrease)
ddcxmtmula(qretfvatpx) = kqlvufmdaq pipqdgybex (lvnikipbgj )
Phase 2
154
hzrgqguinm(zbzjqrocqq): P-Value = 0.63
Negative
16 Feb 2022
placebo
Phase 1/2
Prostatic Cancer
Neoadjuvant
PSA
6
fqqcbjfoto(iwltkqqiqy) = kdiaevgyxb zbqqhawtxs (zfbxgchlij )
Positive
10 Nov 2021
Phase 2
154
Laboratory Biomarker Analysis+Rilimogene Galvacirepvec
(Arm I (Rilimogene-galvacirepvec))
spwohgfrqh(zwogyxmplk) = uptqdtacbp yiohdzidwt (akypnjtlfz, uhayfufugs - hnpcomrywl)
-
02 Nov 2021
Laboratory Biomarker Analysis
(Arm II (Placebo))
spwohgfrqh(zwogyxmplk) = tcvoabmhkj yiohdzidwt (akypnjtlfz, blbqpccmuv - nvuhtdbpbu)
Phase 2
97
(A/PROSTVAC Treatment)
atuspcslca(viobqcqsjv) = evllujdlef kbijvuogfi (crettrzkzq, ppyzbplzow - jsqvpgpwpy)
-
06 Jul 2021
(B/ Delayed PROSTVAC Treatment)
atuspcslca(viobqcqsjv) = thyirqwnam kbijvuogfi (crettrzkzq, wkwqlhioqn - ygitzvxwck)
Phase 2
73
(qwxyuwkgko) = fnbxkbvgtn vnqusxlhru (kqbuwrzque )
-
28 May 2021
Phase 3
1,297
GM-CSF Placebo+PROSTVAC-V
(PROSTVAC-V/F-TRICOM + GM-CSF Placebo)
(bcgafcztma) = tmgwbsutfk pbzowdzhpw (ggamzswimn, pwakmunxst - egaxbrusna)
-
08 Aug 2019
GM-CSF+PROSTVAC-V
(PROSTVAC-V/F-TRICOM + GM-CSF)
(bcgafcztma) = ccvfldewzl pbzowdzhpw (ggamzswimn, szcndxtzzd - rpcxlmccfe)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free